Re: Rok po przejęciu Mesa Biotech

Trudno porównywać Acculę do PCR ONE. Urządzenie Mesy funkcjonalnie jest alternatywą do Abbota ID Now i kilku innych ( to rynek na którym będzie pewnie Genomtec ID).
Ma jednak istotną przewagę jaką jest niski koszt urządzenia, choć nie mogę nigdzie znaleźć informacji o całkowitym koszcie jednego testu ( czyli koszt kasetki i butelki z odczynnikiem)

Poniżej podsumowanie wystąpienia CEO Thermo Fisher sprzed dwóch dni, w którym Casper odnosi się to akwizycji Mesa

Regarding the Mesa Biotech point-of-care rapid PCR system, Casper said the long-term strategy is to build up menu for the handheld device.

"We looked at over 50 different technologies — there are a lot of interesting different technologies and startups — and what we loved about Mesa Biotech's rapid PCR is, the quality of results is awesome, and the instrument is super low-cost," Casper said.

Furthermore, Casper said, "The list price on the instrument is $300, which basically means you can have it everywhere, and it is super easy to use."

Thermo Fisher reasoned that the COVID-related opportunity alone will likely pay for the Mesa acquisition, and the firm can then capitalize with a new menu post-COVID.

The company is now developing other molecular diagnostic tests for the system, including respiratory and other targets that could have utility in decentralized settings needing rapid turnaround times.

"What we would expect is that by the middle of this decade you will see an impressive menu that will allow [spaces like] the pharmac market to be able to offer rapid PCR tests," he said.